MA39048A1 - Nouveaux inhibiteurs de la dgat2 - Google Patents

Nouveaux inhibiteurs de la dgat2

Info

Publication number
MA39048A1
MA39048A1 MA39048A MA39048A MA39048A1 MA 39048 A1 MA39048 A1 MA 39048A1 MA 39048 A MA39048 A MA 39048A MA 39048 A MA39048 A MA 39048A MA 39048 A1 MA39048 A1 MA 39048A1
Authority
MA
Morocco
Prior art keywords
dgat2
new inhibitors
compounds
methods
lilly
Prior art date
Application number
MA39048A
Other languages
English (en)
Other versions
MA39048B1 (fr
Inventor
Nicholas Paul Camp
Manisha Naik
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52016867&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39048(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of MA39048A1 publication Critical patent/MA39048A1/fr
Publication of MA39048B1 publication Critical patent/MA39048B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des composés de la formule ci-dessous : (i) où r désigne h ou -ch3; des méthodes pour traiter des patients atteints d'hypertriglycéridémie et de maladies cardiovasculaires, y compris la dyslipidémie et l'athérosclérose, ainsi que des procédés pour préparer lesdits composés.(71) us:eli lilly and company@lilly corporate centerindianapolis, indiana 46285 @
MA39048A 2013-11-25 2014-11-19 Nouveaux inhibiteurs de la dgat2 MA39048B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361908339P 2013-11-25 2013-11-25
PCT/US2014/066339 WO2015077299A1 (fr) 2013-11-25 2014-11-19 Nouveaux inhibiteurs de la dgat2

Publications (2)

Publication Number Publication Date
MA39048A1 true MA39048A1 (fr) 2017-05-31
MA39048B1 MA39048B1 (fr) 2018-04-30

Family

ID=52016867

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39048A MA39048B1 (fr) 2013-11-25 2014-11-19 Nouveaux inhibiteurs de la dgat2

Country Status (24)

Country Link
US (1) US9073901B2 (fr)
EP (1) EP3074381B1 (fr)
JP (1) JP6155395B2 (fr)
KR (1) KR20160072252A (fr)
CN (1) CN105764889B (fr)
AP (1) AP2016009230A0 (fr)
AR (1) AR098394A1 (fr)
AU (1) AU2014353109B2 (fr)
CA (1) CA2928468A1 (fr)
CL (1) CL2016001172A1 (fr)
CR (1) CR20160216A (fr)
DO (1) DOP2016000120A (fr)
EA (1) EA201690847A1 (fr)
ES (1) ES2695302T3 (fr)
HK (1) HK1223367A1 (fr)
IL (1) IL245245A0 (fr)
MA (1) MA39048B1 (fr)
MX (1) MX2016006665A (fr)
NZ (1) NZ719444A (fr)
PE (1) PE20161099A1 (fr)
PH (1) PH12016500963A1 (fr)
TN (1) TN2016000146A1 (fr)
TW (1) TW201609668A (fr)
WO (1) WO2015077299A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3298001B1 (fr) * 2015-05-20 2020-05-13 Eli Lilly and Company Inhibiteurs de la dgat2
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
GB2606804B (en) 2019-07-17 2023-12-27 2692372 Ontario Inc Benzenesulfonamide derivatives and uses thereof
TWI771766B (zh) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶２ 抑制劑
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
US11787810B2 (en) 2020-05-18 2023-10-17 Merck Sharp & Dohme Llc Diacylglyceride O-acyltransferase 2 inhibitors
PT4225739T (pt) 2020-10-08 2026-04-07 Merck Sharp & Dohme Llc Preparação de derivados de benzimidazolona como novos inibidores da diacilglicerol o-aciltransferase 2
TW202229232A (zh) 2020-10-08 2022-08-01 美商默沙東藥廠 作為新穎二醯基甘油酯o-醯基轉移酶2抑制劑之吲哚酮衍生物的製備
GB2618680A (en) 2020-11-20 2023-11-15 2692372 Ontario Inc Methods and composition for KRAS modifications
WO2022140169A1 (fr) 2020-12-22 2022-06-30 Merck Sharp & Dohme Corp. Préparation de dérivés de tétrahydroindazole en tant que nouveaux inhibiteurs de diacylglycéride o-acyltransférase 2
WO2023026180A1 (fr) 2021-08-26 2023-03-02 Pfizer Inc. Forme amorphe de (s)-2-(5-((3-éthoxypyridin-2-yl)oxy)pyridin-3-yl)-n-(tétrahydrofuran-3-yl)pyrimidine-5-carboxamide
IL321166A (en) 2022-12-02 2025-07-01 Merck Sharp & Dohme Llc Preparation of fused azole derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003053363A2 (fr) 2001-12-19 2003-07-03 Millennium Pharmaceuticals, Inc. Membres de la famille des diacylglycerol-acyltransferases 2 (dgat2) et leurs utilisations
EP1534074A4 (fr) 2002-07-18 2008-01-09 Merck & Co Inc Polytherapie pour le traitement de l'obesite
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
HRP20090093T3 (en) * 2004-06-04 2009-03-31 Arena Pharmaceuticals Inc. Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US20080200376A1 (en) 2004-10-29 2008-08-21 Maccoss Malcolm Compositions and Methods For the Treatment Of Obesity and Sexual Dysfunction
JP5566880B2 (ja) 2007-04-24 2014-08-06 インゲニウム ファーマシューティカルズ ジーエムビーエイチ プロテインキナーゼの阻害剤としての４，６−二置換アミノピリミジン誘導体
JP2013515085A (ja) 2009-12-22 2013-05-02 ジ・アドミニストレイターズ・オブ・ザ・チユレーン・エデユケーシヨナル・フアンド 肥満症および糖尿病を治療するための組成物および方法
WO2011078102A1 (fr) * 2009-12-22 2011-06-30 第一三共株式会社 Nouveau dérivé de phénoxypyrimidine
JP5921525B2 (ja) 2010-03-22 2016-05-24 リード ディスカバリー センター ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬的に活性のある二置換のトリアジン誘導体
JP2014515008A (ja) * 2011-03-03 2014-06-26 ヴァンダービルト ユニバーシティー Ｍｇｌｕｒ５の負のアロステリック調節剤としての６−アルキル−ｎ−（ピリジン−２−イル）−４−アリールオキシピコリンアミド類似体ならびにそれを作製および使用する方法
EP2561867A1 (fr) 2011-08-22 2013-02-27 Lead Discovery Center GmbH Inhibiteurs de CDK9 pour le traitement du carcinome de la ligne médiane
EP2562265A1 (fr) 2011-08-22 2013-02-27 Lead Discovery Center GmbH Sensibilité à des inhibiteurs sélectifs de CDK9
SG11201405477XA (en) * 2012-04-06 2014-11-27 Pfizer Diacylglycerol acyltransferase 2 inhibitors

Also Published As

Publication number Publication date
CN105764889A (zh) 2016-07-13
US20150148358A1 (en) 2015-05-28
EP3074381A1 (fr) 2016-10-05
MX2016006665A (es) 2016-07-26
AP2016009230A0 (en) 2016-05-31
WO2015077299A1 (fr) 2015-05-28
IL245245A0 (en) 2016-06-30
KR20160072252A (ko) 2016-06-22
AU2014353109B2 (en) 2017-02-02
ES2695302T3 (es) 2019-01-03
NZ719444A (en) 2017-12-22
AU2014353109A1 (en) 2016-05-12
JP2016539115A (ja) 2016-12-15
EP3074381B1 (fr) 2018-07-04
MA39048B1 (fr) 2018-04-30
TN2016000146A1 (en) 2017-10-06
DOP2016000120A (es) 2016-06-15
CL2016001172A1 (es) 2016-12-09
TW201609668A (zh) 2016-03-16
US9073901B2 (en) 2015-07-07
CR20160216A (es) 2016-06-27
EA201690847A1 (ru) 2016-09-30
JP6155395B2 (ja) 2017-06-28
CA2928468A1 (fr) 2015-05-28
PH12016500963A1 (en) 2016-06-20
HK1223367A1 (zh) 2017-07-28
PE20161099A1 (es) 2016-10-22
AR098394A1 (es) 2016-05-26
CN105764889B (zh) 2018-01-02

Similar Documents

Publication Publication Date Title
MA39048B1 (fr) Nouveaux inhibiteurs de la dgat2
MA38050A1 (fr) Inhibiteurs de gdf-8
EA201490493A1 (ru) Пирано[3,2-d][1,3]тиазол в качестве ингибиторов гликозидазы
NZ630196A (en) Cyclic amides as metap-2 inhibitors
IN2012DN00692A (fr)
MX2012001618A (es) Derivados de 5-fluoropirimidinona.
NZ749557A (en) 3-alkyl-5-fluoro-4-substituted-imino-3,4-dihydropyrimidin-2(1h)-one derivatives as fungicides
EA201391290A1 (ru) Гетероциклические модуляторы синтеза липидов
MA35434B1 (fr) Amino-quinazolines en tant qu'inhibiteurs de kinase
PH12012502138B1 (en) N3-substituted-n1-sulfonyl-5-fluoropyrimidinone derivatives
MA35351B1 (fr) Nouveau dérivé 1,2,3,4- tétrahydroquinoléine utile pour le traitement du diabète.
MA38239A1 (fr) Nouveaux dérivés de pyridine
MA33840B1 (fr) Nouveau composé de spiropipéridine
MA35016B1 (fr) Imidazopyridazines en gtant qu'inhibiteurs de la kinase akt
MA38218A1 (fr) Pyridine-2-amides utiles comme agonistes de cb2
IN2012DN00695A (fr)
EA201590561A1 (ru) Пролекарства аминохиназолинового ингибитора киназы
MA40895A (fr) Synthèse de copanlisib et son sel de dichlorhydrate
MX2012001617A (es) Derivados de 5-fluoro-2-oxopirimidina-1 (2h)-carboxamida substituida-n1.
MX2012001620A (es) Derivados de n1-acil-5-fluoropirimidinona.
NZ740727A (en) Phenyl derivatives as cannabinoid receptor 2 agonists
EA201491227A1 (ru) Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2
JO3248B1 (ar) عملية لتحضير إنزيمات مثبطة من نوع c-fms
MX2019011261A (es) Compuestos de isoxazol carboxamida y sus usos.
EA201100350A1 (ru) Противогрибковые средства